GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$1.64 USD
-0.07 (-4.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.76 +0.12 (7.32%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
GlycoMimetics, Inc. [GLYC]
Reports for Purchase
Showing records 101 - 120 ( 157 total )
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
1Q20 Results; Phase 3 Uproleselan Enrollment Slowed in April; Cash Runway for Two Years
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
1Q20 Update - Strong Cash Position - Impact of COVID-19 on Timelines TBD
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
COVID-19 Update: Cash Position - 2020 Catalysts of Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
New VP of Reg Affairs Dr. Herrle to Bring Upro to Finish Line in r/r AML
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Our Presenting Companies at the ROTH Conference and 2020 Catalyst Calendar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Our Presenting Companies at the ROTH Conference and 2020 Catalyst Calendar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q19 Update- Potential Value-Driving Catalysts for GlycoMimetics in 2020
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q19 Results; Uproleselan Phase 3 Expected to Complete Enrollment in 2H21; Lowering PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Pfizer Terminates License Agreement with GlycoMimetics - Impact Minimal
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
GMI-1359 Receives FDA Designations; U.S. Patent Also Issued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Apollomics Partnership Builds Further Confidence in E-Selectin Platform
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Agreement for Uproleselan and GMI-1687 Development and Commercialization in Greater China
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Dear Merck, I''m Pleased to Introduce You to GlycoMimetics'' Uproleselan
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z